ATR and head and neck squamous cell carcinoma: The addition of 0.5 μM of AZD6738 inhibited the phosphorylation of CHK1 both in monotherapy and in the combination treatment conditions (Figure 4), further confirming that ATR inhibition radiosensitized HNSCC cells through cell cycle checkpoint inhibition.